LLY catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 2NCT01025089Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic CarcinomaMemorial Sloan Kettering Cancer Center · ThymomaActive, not recruitingLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT03527108Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLCFox Chase Cancer Center · Non Small Cell Lung CancerActive, not recruitingBMYCollaboratorLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT03909334Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Xiuning Le · Non Small Cell Lung CancerActive, not recruitingLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT07169851A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With CancerEli Lilly and Company · NauseaRecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07225556A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise HealthyEli Lilly and Company · OverweightActive, not recruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07738614A Study of Eloralintide (LY3841136) in Participants With Obesity or OverweightEli Lilly and Company · ObesityActive, not recruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07803744A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or ObesityEli Lilly and Company · Diabetes Mellitus, Type 1RecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07867327A Study of LY4515100 in Healthy Male ParticipantsEli Lilly and Company · HealthyRecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT07889453Metabolic Effects of Switching From Injectable Semaglutide to TirzepatideLMC Diabetes & Endocrinology Ltd. · ObesityActive, not recruitingLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 2NCT04393285Abemaciclib and Letrozole to Treat Endometrial CancerGynecologic Oncology Group · Endometrial CancerActive, not recruitingLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 2NCT05305924Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast CancerThe Methodist Hospital Research Institute · ER-Positive Breast CancerRecruitingLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2, 2026Sponsor estimatePhase 1/Phase 2NCT04285671Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor...Jonsson Comprehensive Cancer Center · Metastatic Lung Non-Small Cell CarcinomaActive, not recruitingLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 22, 2026Sponsor estimateNo phase registeredNCT05254795Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual CareTimothy Mullett · Non-Small Cell Lung CancerActive, not recruitingLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 25, 2026Sponsor estimateNo phase registeredNCT07063316SGLT2 Inhibitors and Renal Anemia in Japan: RWDBoehringer Ingelheim · Chronic Kidney DiseaseActive, not recruitingLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06989281Evaluation of a Primary Care Based Lifestyle Medicine Clinic at UABUniversity of Alabama at Birmingham · Obesity and Obesity-related Medical ConditionsEnrolling by invitationLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 2027Sponsor estimateNo phase registeredNCT01155245Teriparatide (PTH) and Bone Strength in Postmenopausal WomenUniversity Health Network, Toronto · OsteoporosisActive, not recruitingLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1NCT05714072A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of MyelofibrosisMemorial Sloan Kettering Cancer Center · Myelofibrosis Due to and Following Polycythemia VeraRecruitingLLYCollaboratorINCYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1NCT06982859A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes...Eli Lilly and Company · Diabetes MellitusActive, not recruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1NCT07765498A Study of LY4355756 in Healthy ParticipantsEli Lilly and Company · HealthyRecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1NCT07867340A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants...Eli Lilly and Company · C-Reactive ProteinRecruitingLLYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2027Sponsor estimatePhase 2NCT03310879Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or...Dana-Farber Cancer Institute · CancerRecruitingLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 21 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.